Construction of a immune-associated genes based prognostic signature in bladder cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Compérat EM, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) – 2019 update. Eur Urol. 2019;76(5):639–657.
   PubMed Web of Science ®Google Scholar
• Poli G, Egidi MG, Cochetti G, et al. Relationship between cellular and exosomal miRNAs targeting NOD-like receptors in bladder cancer: preliminary results. Minerva Urol Nefrol. 2020;72(2):207–213.
   PubMed Web of Science ®Google Scholar
• Mearini E, Poli G, Cochetti G, et al. Expression of urinary miRNAs targeting NLRs inflammasomes in bladder cancer. Onco Targets Ther. 2017;10:2665–2673.
   PubMed Web of Science ®Google Scholar
• Poli G, Brancorsini S, Cochetti G, et al. Expression of inflammasome-related genes in bladder cancer and their association with cytokeratin 20 messenger RNA. Urol Oncol. 2015;33(12):505.e1–505.e7.
   PubMed Web of Science ®Google Scholar
• Schneider AK, Chevalier MF, Derré L. The multifaceted immune regulation of bladder cancer. Nat Rev Urol. 2019;16(10):613–630.
   PubMed Web of Science ®Google Scholar
• Saad FT, Hincal E, Kaymakamzade B. Dynamics of immune checkpoints, immune system, and BCG in the treatment of superficial bladder cancer. Comput Math Methods Med. 2017;2017:3573082.
   PubMed Web of Science ®Google Scholar
• Poli G, Cochetti G, Boni A, et al. Characterization of inflammasome-related genes in urine sediments of patients receiving intravesical BCG therapy. Urol Oncol. 2017;35(12):674.e19–674.e24.
   Web of Science ®Google Scholar
• Felsenstein KM, Theodorescu D. Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. Nat Rev Urol. 2018;15(2):92–111.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Andorf S, Gomes L, et al. ImmPort: disseminating data to the public for the future of immunology. Immunol Res. 2014;58(2–3):234–239.
   PubMed Web of Science ®Google Scholar
• Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–140.
   PubMed Web of Science ®Google Scholar
• Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1–22.
   PubMed Web of Science ®Google Scholar
• Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2018;174(4):1033.
   PubMed Web of Science ®Google Scholar
• Shen C, Liu J, Wang J, et al. Development and validation of a prognostic immune-associated gene signature in clear cell renal cell carcinoma. Int Immunopharmacol. 2020;81:106274.
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110.
   PubMed Web of Science ®Google Scholar
• Chanput W, Mes JJ, Wichers HJ. THP-1 cell line: an in vitro cell model for immune modulation approach. Int Immunopharmacol. 2014;23(1):37–45.
   PubMed Web of Science ®Google Scholar
• Martínez VG, Rubio C, Martínez-Fernández M, et al. BMP4 induces M2 macrophage polarization and favors tumor progression in bladder cancer. Clin Cancer Res. 2017;23(23):7388–7399.
   PubMed Web of Science ®Google Scholar
• Chen C, He W, Huang J, et al. LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment. Nat Commun. 2018;9(1):3826.
   PubMed Web of Science ®Google Scholar
• Cornely R, Pollock AH, Rentero C, et al. Annexin A6 regulates interleukin-2-mediated T-cell proliferation. Immunol Cell Biol. 2016;94(6):543–553.
   PubMed Web of Science ®Google Scholar
• Keklikoglou I, Cianciaruso C, Güç E, et al. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nat Cell Biol. 2019;21(2):190–202.
   PubMed Web of Science ®Google Scholar
• Leca J, Martinez S, Lac S, et al. Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. J Clin Invest. 2016;126(11):4140–4156.
   PubMed Web of Science ®Google Scholar
• Chen Q, Zheng W, Zhu L, et al. ANXA6 contributes to radioresistance by promoting autophagy via inhibiting the PI3K/AKT/mTOR signaling pathway in nasopharyngeal carcinoma. Front Cell Dev Biol. 2020;8:232.
   PubMed Web of Science ®Google Scholar
• Lee H, Kim K, Woo J, et al. Quantitative proteomic analysis identifies AHNAK (neuroblast differentiation-associated protein AHNAK) as a novel candidate biomarker for bladder urothelial carcinoma diagnosis by liquid-based cytology. Mol Cell Proteomics. 2018;17(9):1788–1802.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liu X, Huang R, et al. Upregulation of nucleoprotein AHNAK is associated with poor outcome of pancreatic ductal adenocarcinoma prognosis via mediating epithelial–mesenchymal transition. J Cancer. 2019;10(16):3860–3870.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Xiao S, Yuan X, et al. AHNAK as a prognosis factor suppresses the tumor progression in glioma. J Cancer. 2017;8(15):2924–2932.
   PubMed Web of Science ®Google Scholar
• Matza D, Flavell RA. Roles of Ca(v) channels and AHNAK1 in T cells: the beauty and the beast. Immunol Rev. 2009;231(1):257–264.
   PubMed Web of Science ®Google Scholar
• Park JW, Kim IY, Choi JW, et al. AHNAK loss in mice promotes type II pneumocyte hyperplasia and lung tumor development. Mol Cancer Res. 2018;16(8):1287–1298.
   PubMed Web of Science ®Google Scholar
• Chen X, Mo P, Li X, et al. CacyBP/SIP protein promotes proliferation and G1/S transition of human pancreatic cancer cells. Mol Carcinog. 2011;50(10):804–810.
   PubMed Web of Science ®Google Scholar
• Niu YL, Li YJ, Wang JB, et al. CacyBP/SIP nuclear translocation regulates p27Kip1 stability in gastric cancer cells. World J Gastroenterol. 2016;22(15):3992–4001.
   PubMed Web of Science ®Google Scholar
• Lian YF, Huang YL, Zhang YJ, et al. CACYBP enhances cytoplasmic retention of P27Kip1 to promote hepatocellular carcinoma progression in the absence of RNF41 mediated degradation. Theranostics. 2019;9(26):8392–8408.
   PubMed Web of Science ®Google Scholar
• Nie F, Yu XL, Wang XG, et al. Down-regulation of CacyBP is associated with poor prognosis and the effects on COX-2 expression in breast cancer. Int J Oncol. 2010;37(5):1261–1269.
   PubMed Web of Science ®Google Scholar
• Chen X, Zheng P, Xue Z, et al. CacyBP/SIP enhances multidrug resistance of pancreatic cancer cells by regulation of P-gp and Bcl-2. Apoptosis. 2013;18(7):861–869.
   PubMed Web of Science ®Google Scholar
• Tang Y, Zhan W, Cao T, et al. CacyBP/SIP inhibits doxourbicin-induced apoptosis of glioma cells due to activation of ERK1/2. IUBMB Life. 2016;68(3):211–219.
   PubMed Web of Science ®Google Scholar
• Kang YH, Biswas A, Field M, et al. STAT1 signaling shields T cells from NK cell-mediated cytotoxicity. Nat Commun. 2019;10(1):912.
   PubMed Web of Science ®Google Scholar
• Kemmner S, Bachmann Q, Steiger S, et al. STAT1 regulates macrophage number and phenotype and prevents renal fibrosis after ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2019;316(2):F277–F291.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li X, Tan F, et al. STAT1 inhibits MiR-181a expression to suppress colorectal cancer cell proliferation through PTEN/Akt. J Cell Biochem. 2017;118(10):3435–3443.
   PubMed Web of Science ®Google Scholar
• Ryan N, Anderson K, Volpedo G, et al. STAT1 inhibits T-cell exhaustion and myeloid derived suppressor cell accumulation to promote antitumor immune responses in head and neck squamous cell carcinoma. Int J Cancer. 2020;146(6):1717–1729.
   PubMed Web of Science ®Google Scholar
• Liu XL, Zhao D, Sun DP, et al. Adenovirus-mediated delivery of CALR and MAGE-A3 inhibits invasion and angiogenesis of glioblastoma cell line U87. J Exp Clin Cancer Res. 2012;31(1):8.
   PubMed Web of Science ®Google Scholar
• Kasikova L, Hensler M, Truxova I, et al. Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients. J Immunother Cancer. 2019;7(1):312.
   PubMed Web of Science ®Google Scholar
• Liu P, Zhao L, Loos F, et al. Immunosuppression by mutated calreticulin released from malignant cells. Mol Cell. 2020;77(4):748–760.e9.
   PubMed Web of Science ®Google Scholar